Ectopic ULBP2 Is Associated with Decreased NKG2D Expression in CD8+ T Cells Under T Cell-Modulatory Conditions in a Murine Tumor Model
Cells · 13.06.2025 · 14 (12) · 893
DOI: 10.3390/cells14120893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 13.06.2025. Verfasst von Yasuhiko Teruya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, 36-1 N…. Hauptthemen laut MEDLINE: NK Cell Lectin-Like Receptor Subfamily K, CD8-Positive T-Lymphocytes, Intercellular Signaling Peptides and Proteins, Colonic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
UL16-binding protein 2 (ULBP2), a ligand for the activating receptor NKG2D, plays a dual role in tumor immunity, promoting immune activation or suppression, depending on the context. To investigate its impact on CD4+CD25+ T cell-targeted immunotherapies, we used a syngeneic CT26 colon cancer model engineered to express ULBP2 and compared tumor growth and tumor-infiltrating lymphocyte (TIL) profiles in control and ULBP2-expressing tumors treated with anti-CD4, anti-CD25, or anti-CTLA-4 antibodies. Tumor growth was uniformly assessed on day 21 post-transplantation, and TIL analysis was performed in groups with evaluable residual tumors. Anti-CD4 antibody significantly suppressed tumor growth in mock-transfected tumors, while no significant suppression was observed in ULBP2-expressing tumors. Anti-CD25 antibody had limited efficacy in mock tumors and tended to promote tumor growth in ULBP2-expressing tumors. Following these treatments, ULBP2 expression was associated with reduced NKG2D expression in CD8+ effector memory T cells, particularly PD-1high subsets. In contrast, anti-CTLA-4 antibody treatment induced marked tumor regression irrespective of ULBP2 expression. These findings suggest that ULBP2–NKG2D signaling may contribute to altered CD8+ T cell phenotypes under T cell-modulatory conditions, potentially impacting the outcome of CD4+CD25+ T cell-targeted therapies and providing insights for optimizing immunotherapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan.
- Division of Radioisotope Science, Research Initiative Center, Organization for Research Initiative and Promotion, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan.
- Division of Infectious Diseases, School of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan.
ORCID-Profile: Kosuke Yamaguchi, Akira Yamasaki
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Teruya, Y., Yamaguchi, K., Yamane, K., Miyake, N., Nakayama, Y., Nonaka, T., Chikumi, H., & Yamasaki, A. (2025). Ectopic ULBP2 Is Associated with Decreased NKG2D Expression in CD8+ T Cells Under T Cell-Modulatory Conditions in a Murine Tumor Model. Cells, 14(12), 893. https://doi.org/10.3390/cells14120893
Vancouver
Teruya Y, Yamaguchi K, Yamane K, Miyake N, Nakayama Y, Nonaka T, et al. Ectopic ULBP2 Is Associated with Decreased NKG2D Expression in CD8+ T Cells Under T Cell-Modulatory Conditions in a Murine Tumor Model. Cells. 2025;14(12):893. doi:10.3390/cells14120893
BibTeX
@article{Teruya2025,
author = {Teruya, Yasuhiko and Yamaguchi, Kosuke and Yamane, Kohei and Miyake, Naomi and Nakayama, Yuji and Nonaka, Takafumi and Chikumi, Hiroki and Yamasaki, Akira},
title = {Ectopic ULBP2 Is Associated with Decreased NKG2D Expression in CD8+ T Cells Under T Cell-Modulatory Conditions in a Murine Tumor Model},
journal = {Cells},
year = {2025},
volume = {14},
number = {12},
pages = {893},
doi = {10.3390/cells14120893}
}
EUVIMED